Should every patient with diabetes receive a statin?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 7-8, 2008, Pages 398-401

  Dembowski, Ewa ^a   Davidson, Michael H ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; FOLLOW UP; HEALTH HAZARD; HEART MUSCLE REVASCULARIZATION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MONOTHERAPY; MORBIDITY; MORTALITY; MYOPATHY; OUTCOME ASSESSMENT; PREVALENCE; RISK REDUCTION; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 49249117425     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.430     Document Type: Editorial

References (29)

1. Garcia MJ, McNamara PM, Gordon T, Kannell WB. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes. 1974; 23: 105-111.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993; 16: 434-444.
3. Lebovitz HE, Austin MM, Blonde L, et al.; for the ACE/AACE Diabetes Recommendations Implementation Writing Committee. ACE/AACE consensus conferences on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006; 12 (Suppl): 6-12.
4. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes; a randomized placebo-controlled trial. Lancet. 2003; 361: 2005-2016.
5. Waters DD, Guyton JR, Herrington DM, et al.; for the TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: Does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004; 93: 154-158.
6. Pedersen TR, Faergeman O, Kastelein JJ, et al.; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294: 2437-2445.
7. Davidson MH. Reducing residual risk for patient on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005; 96 (Suppl): K3- K13.
8. Clearfield M, Downs JR, Lee M, et al. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. Am J Cardiol. 2005, 96: 1674-1680.
9. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel III). Executive summary of the third report of the national cholesterol education program (NCEP). JAMA. 2001; 285: 2486-2497.
10. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239.
11. LaRosa JC, Grundy SM, Waters DD, et al., for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352: 1425-1435.
12. Colhoun HM, Betteridge DJ, Durrington PN, et al.; for the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatn Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet. 2004; 364: 685-696.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2008. Diabetes Care. 2008; 31 (Suppl 1): S12-S54.
14. Scandinivian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389.
15. Ridker PM, Rifai N, Pfeffer MA, et al. Long term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999; 100: 230-235.
16. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with CHD and a brand range of initial cholesterol levels. N Engl J Med. 1998; 339: 1349-1357.
17. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002; 106: 2526-2529.
18. Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem. 2004; 50: 1184-1188.
19. Stein EA, Sniderman A, Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol. 2005; 96: K36-K43.
20. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/ Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000; 101: 477-484.
21. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008; 31: 811-822.
22. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998; 98: 731-733.
23. Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. Am J Cardiol. 2005; 45: 1644-1648.
24. Ridker PM, on behalf of JUPITER study group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity c-reactive protein. Rationale and design of the JUPITER Trial. Circulation. 2003; 108: 2292-2297.
25. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholsterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey: implications for treatment under the recent NCP Writing Group recommendations. Am J Cardiol. 2005; 96: 556-563.
26. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006; 28: 26-35.
27. Davidson MH. Emerging therapeutic strategies for management of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol. 2004; 93: C3-C11.
28. Davidson MH, Ballantyne CM, Kerzner B, et al.; for the Ezetimibe study group. Efficacy and safety of exetmibide coadministered with statins: randomized, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004; 58: 746-755.
29. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (FIELD study): Randomized controlled trial. Lancet. 2005; 366: 1849-1861.